Speedboat® UltraSlim: US FDA Clearance

Creo Medical Group PLC

01 November 2023

 

Creo Medical Group plc

("Creo", the "Group" or the "Company")

Speedboat® UltraSlim: US FDA Clearance

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy, is pleased to announce that it has received 510(k) clearance from the US Food & Drug Administration ("FDA") for its Speedboat® UltraSlim device.

FDA clearance allows the Company to initiate the launch of UltraSlim in the USA through its existing direct sales force and supported by its network of key opinion leaders and clinicians. Clearance follows recent guidance received from the Company's notified body of an EU regulatory pathway which has accelerated the European launch of the UltraSlim device by approximately 18 months.

Speedboat® UltraSlim is the second brand in Creo's Speedboat® family of devices alongside Speedboat Inject and offers a number of different features. The primary feature is the reduced size in comparison with the Speedboat Inject. This results in the device being compatible with all endoscopes with a 2.8mm working channel or larger, accounting for the vast majority of GI endoscopic procedures and significantly increasing the opportunity for more clinicians and patients to benefit from Creo's cutting-edge technology.

The UltraSlim device is targeting the therapeutic treatment of Gastrointestinal ("GI") tract lesions (including Bowel and Upper GI cancers, and pre-cancerous lesions) and swallowing disorders. Powered by Creo's CROMA advanced energy platform, the UltraSlim delivers advanced bi-polar Radiofrequency ("RF") energy for controlled cutting and high frequency microwave ("MW") energy for controlled coagulation of tissue in the GI tract.

Craig Gulliford, Chief Executive Officer of Creo, said: "We are delighted to receive FDA clearance for Speedboat UltraSlim, which is testament to the hard work of our entire team. Our engineering team have overcome many challenges to scale the Speedboat technology down to the size of the UltraSlim, and, with the support of our regulatory team, we have been able to obtain FDA clearance with speed and efficiency.

"Together with the recent news of the accelerated regulatory pathway in the EU, we look forward to patients, clinicians and healthcare providers being able to benefit from the widespread commercialisation of Speedboat UltraSlim in both Europe and the US in 2024 and beyond."

Enquiries:

Creo Medical Group plc	www.creomedical.com
Richard Rees (CFO)	[phone]
Cavendish Capital Markets Limited	[phone]
Stephen Keys / Camilla Hume (NOMAD) Nigel Birks / Harriet Ward (Corporate Broking)
Michael Johnson (Sales)
Deutsche Numis (Joint Broker) Freddie Barnfield / Duncan Monteith / Euan Brown	[phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Sam Allen / Phillip Marriage	Mob: [phone]

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

 

END